Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estafilocinasa No Inmunogénica en Bolo Único en Pacientes con Accidente Cerebrovascular Isquémico Agudo Dentro de las 4.5-24 Horas del Inicio de los Síntomas (FRIDA-CT)

10 de noviembre de 2026 actualizado por: Supergene, LLC

Estudio multicéntrico, doble ciego, aleatorizado y controlado con placebo de la eficacia y seguridad de la estafilocinasa recombinante no inmunogénica en pacientes con accidente cerebrovascular isquémico agudo dentro de las 4,5-24 horas tras el inicio de los síntomas (FRIDA-CT)

Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

The current guidelines recommended intravenous thrombolysis as the first-line treatment for acute large vessel occlusion of anterior circulation stroke within 4.5 hours of stroke onset. However, a majority of patients arrive in the hospital outside the 4.5-hour time window, who could not receive intravenous thrombolysis.

In 2020, the non-immunogenic staphylokinase was registered in Russia for the acute ischemic stroke treatment within 4,5 h after the onset of symptoms. In the FRIDA randomized clinical trial the non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus of 10 mg regardless patients' bodyweight, simplifying clinical use. In 2024, the non-immunogenic staphylokinase has been included in the updated Russian clinical guidelines for the acute ischemic stroke treatment.

A rapid (10 s) single bolus of the non-immunogenic staphylokinase in patients with acute ischemic stroke may provide significant advantages over a one-hour alteplase administration in the more rapid reperfusion in the first 24 hours after thrombolysis and a greater number of good functional outcomes. It can be assumed that the non-immunogenic staphylokinase usage in patients with acute ischemic stroke outside the 4.5-hour therapeutic window will lead to the restoration of collateral blood flow in the penumbra in comparison with standard medical management.

Therefore, FRIDA-CT trial is aimed to investigate the efficacy and safety of the non-immunogenic staphylokinase within the time window of 4.5-24 hours, wake-up stroke or no witness stroke in patients who had an acute ischaemic stroke with salvageable tissue due to large vessel occlusion.

In the multicenter, double-blind, randomized, placebo-controlled phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume <70 mL, mismatch ratio ≥1.8 and mismatch volume ≥15 mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) will be included and randomised to the non-immunogenic staphylokinase, 10 mg (single bolus) regardless patient's bodyweight or placebo group. Patients who are intended for direct thrombectomy will be excluded from the trial. Follow-up period will be 90 days.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

1050

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Nikolay A. Shamalov, MD, prof
  • Número de teléfono: +7 (499) 936-99-37
  • Correo electrónico: shamalovn@gmail.com

Copia de seguridad de contactos de estudio

  • Nombre: Natalya A. Marskaya
  • Número de teléfono: +7 (499) 936-99-37
  • Correo electrónico: marskayana@gmail.com

Ubicaciones de estudio

      • Chelyabinsk, Rusia
        • Reclutamiento
        • Chelyabinsk Regional Clinical Hospital No. 3
        • Contacto:
        • Investigador principal:
          • Dmitry V. Popov, PhD
      • Irkutsk, Rusia, 664079
        • Reclutamiento
        • Irkutsk Regional Clinical Hospital
        • Contacto:
        • Investigador principal:
          • Ivan V. Korobeynikov, PhD
      • Kazan', Rusia, 420101
        • Reclutamiento
        • Interregional Clinical and Diagnostic Center
        • Contacto:
        • Investigador principal:
          • Dina R. Khasanova, MD, Prof
      • Krasnodar, Rusia, 350086
        • Reclutamiento
        • S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1
        • Contacto:
        • Investigador principal:
          • Ludmila V. Timchenko, MD, prof
      • Krasnogorsk, Rusia, 143408
        • Reclutamiento
        • Krasnogorsk Clinical Hospital
        • Contacto:
          • Svetlana V. Alexandrova
          • Número de teléfono: +7 (498) 602-03-73
          • Correo electrónico: clairalex@mail.ru
        • Investigador principal:
          • Svetlana V. Alexandrova
      • Moscow, Rusia, 108814
        • Reclutamiento
        • Moscow Multidisciplinary Clinical Center "Kommunarka"
        • Contacto:
        • Investigador principal:
          • Denis N. Protsenko, PhD
      • Moscow, Rusia, 117997
        • Reclutamiento
        • N.I. Pirogov Russian National Research Medical University
        • Contacto:
        • Investigador principal:
          • Larisa L. Korsunskaya, MD, Prof
      • Nizhny Novgorod, Rusia, 603126
        • Aún no reclutando
        • N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
        • Contacto:
          • Valentina N. Nesterova, PhD
          • Número de teléfono: +7 (831) 438-95-38
          • Correo electrónico: nesterova-78@mail.ru
        • Investigador principal:
          • Valentina N. Nesterova, PhD
      • Orenburg, Rusia
        • Reclutamiento
        • V.I. Voynov Orenburg Regional Clinical Hospital
        • Contacto:
        • Investigador principal:
          • Alexandr N. Chirkov, PhD
      • Saint Petersburg, Rusia, 193079
        • Reclutamiento
        • St. Petersburg Hospital for War Veterans
        • Contacto:
          • Maria A. Privalova, PhD
          • Número de teléfono: +7 (812) 670-94-44
          • Correo electrónico: privamariya@yandex.ru
        • Investigador principal:
          • Maria A. Privalova, PhD
      • Saint Petersburg, Rusia, 194291
        • Reclutamiento
        • Leningradskaya Regional Clinical Hospital
        • Contacto:
        • Investigador principal:
          • Natalya V. Zhukovskaya, MD, prof
      • Solnechnogorsk, Rusia, 141508
        • Aún no reclutando
        • Solnechnogorsk District Hospital
        • Investigador principal:
          • Anton G. Koledinsky, MD, PhD
        • Contacto:
          • Anton G. Koledinsky, MD, PhD
          • Número de teléfono: +7 (496) 264-14-56
          • Correo electrónico: koledant@mail.ru
      • Tver', Rusia, 170036
        • Reclutamiento
        • Tver Regional Clinical Hospital
        • Contacto:
          • Ksenia V. Khoroshavina
          • Número de teléfono: +7 (482) 277-54-65
          • Correo electrónico: kseniarep@mail.ru
        • Investigador principal:
          • Ksenia V. Khoroshavina
      • Ulyanovsk, Rusia
        • Reclutamiento
        • Ulyanovsk Regional Clinical Hospital
        • Contacto:
        • Investigador principal:
          • Irina V. Greshnova, PhD
      • Volgograd, Rusia, 400138
        • Reclutamiento
        • City Clinical Hospital of Emergency Medical Care No. 25
        • Contacto:
        • Investigador principal:
          • Eduard A. Ponomarev, MD, prof
      • Yekaterinburg, Rusia, 620102
        • Reclutamiento
        • Sverdlovsk Regional Clinical Hospital No. 1
        • Contacto:
        • Investigador principal:
          • Andrey M. Alasheev, MD, prof
    • Ryazan Oblast
      • Ryazan, Ryazan Oblast, Rusia, 390039
        • Aún no reclutando
        • Ryazan Regional Clinical Hospital
        • Contacto:
        • Investigador principal:
          • Sergei B. Aksentyev, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Men and women aged 18 years and over;
  2. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
  3. Pre-stroke modified Rankin scale (mRS) score≤1;
  4. Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;
  5. Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume <70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;
  6. Alberta Stroke Program Early CT score (ASPECTS) > 6;
  7. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);
  8. The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;
  9. Written informed consent from patients or their legally authorized representatives.

Exclusion Criteria:

  1. Acute ischemic stroke within 4,5 h after symptom onset;
  2. Intended to proceed to endovascular treatment;
  3. Known hypersensitivity to the non-immunogenic staphylokinase;
  4. Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;
  5. Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;
  6. Blood glucose <2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);
  7. Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;
  8. Subarachnoid hemorrhage;
  9. Major bleeding currently or within the past 6 months;
  10. Surgery on the brain or spinal cord in the last 2 months;
  11. Punctures of non-compressible arteries and veins in the last 7 days;
  12. Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;
  13. Platelet count below 100,000/mm3;
  14. Previous stroke or severe traumatic brain injury within 3 months;
  15. Unable to perform CT or MRI;
  16. History of hemorrhagic stroke or stroke of unspecified genesis;
  17. Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
  18. Concomitant use of indirect oral anticoagulants (warfarin) with INR > 1.7;
  19. Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;
  20. Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).
  21. Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;
  22. Acute pancreatitis;
  23. Bacterial endocarditis, pericarditis;
  24. Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;
  25. Cancer with an increased risk of bleeding;
  26. Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;
  27. Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);
  28. Hemorrhagic diathesis, including renal and hepatic failure;
  29. Data on bleeding or acute trauma (fracture) at the time of examination;
  30. Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Placebo

Placebo

Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization

Experimental: Non-immunogenic staphylokinase

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight

Otros nombres:
  • Fortelyzin®

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Excellent functional outcome
Periodo de tiempo: 90 days

The number of patients with excellent functional outcome defined as an mRS score 0-1 at 90 days

90 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Ordinal distribution of mRS
Periodo de tiempo: 90 days

Ordinal distribution of mRS at 90 days

90 days
Functional independence outcome
Periodo de tiempo: 90 days

The number of patients with functional independence defined by an mRS score 0-2 point at 90 days

90 days
NIHSS change from baseline
Periodo de tiempo: 7-14 days

NIHSS median change from baseline on discharge

7-14 days
The rate of improvement on reperfusion
Periodo de tiempo: 24 hours

The number of patients with recanalization of 2 and 3 points on the arterial occlusion scale (rAOL) 24 hours after drug administration according to CT (MRI) angiography, where 0 points - complete occlusion, 3 points - complete recanalization.

24 hours
All-cause mortality
Periodo de tiempo: 90 days

Rate of all-cause mortality within 90 days

90 days
Poor functional outcome
Periodo de tiempo: 90 days

The number of patients with poor functional outcome defined by an mRS score 5-6 point at 90 days

90 days

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Hemorrhagic transformation
Periodo de tiempo: 24 hours

Rate of hemorrhagic transformation according to The Heidelberg Bleeding Classification within 24 hours

24 hours
Symptomatic intracranial hemorrhage
Periodo de tiempo: 24 hours

Rate of symptomatic intracranial hemorrhage (sICH) (as defined by The European Cooperative Acute Stroke Study III criteria [ECASSIII] and Safe Implementation of Thrombolysis in Stroke-Monitoring Study [SITS-MOST]) within 24 hours

24 hours
Major bleeding
Periodo de tiempo: 90 days

Rate of major bleeding at 90 days (as defined by the Bleeding Academic Research Consortium (BARC) scale: type 3 and type 5)

90 days
Serious adverse events (SAEs)
Periodo de tiempo: 90 days

Rate of serious adverse events (SAEs) within 90 days

90 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Nikolay A. Shamalov, MD, prof, Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
  • Director de estudio: Sergey S. Markin, MD, prof, LLC "SuperGene"

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

9 de junio de 2026

Finalización primaria (Estimado)

1 de noviembre de 2028

Finalización del estudio (Estimado)

1 de enero de 2029

Fechas de registro del estudio

Enviado por primera vez

23 de diciembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

23 de diciembre de 2025

Publicado por primera vez (Actual)

8 de enero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • FRIDA-CT

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The funder of the study is committed to the responsible sharing of data from FRIDA-CT trail. Data will be provided to any qualified investigator on reasonable request. Deidentified participant data will be available after the publication of the results of the completed study on request to the corresponding author.

Marco de tiempo para compartir IPD

within 90 days after request

Criterios de acceso compartido de IPD

Proposals will be reviewed and approved by the funder and Data and Safety Monitoring Board. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .